Back to Archived News
MAP Pharmaceuticals Issued Additional U.S. Patent for Methods of Achieving Rapid Treatment of Migraine Based Upon Pharmacokinetic Profile
Thursday, February 23, 2012
Mountain View, CA -- MAP Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) issued to the Company U.S. Patent No. 8,119,639, titled "Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile." The patent, which expires in 2028, results from the Company's discovery that dihydroergotamine (DHE) can be administered to achieve pharmacokinetic profiles that result in rapid efficacy while minimizing side effects that are typically seen with other migraine drugs. The patent claims relate to pulmonary administration of DHE to achieve certain pharmacokinetic profiles. LEVADEX®, which contains the Company's proprietary formulation of DHE, is an orally inhaled investigational drug administered using the Company's proprietary TEMPO® inhaler for the potential acute treatment of migraine in adults and targets the pharmacokinetic profiles described in this patent. DHE is a drug that is currently available in other dosage forms to treat migraine.
"The issuance of this patent adds further protection to the Company's growing patent estate relating to our LEVADEX product candidate," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "This patent, which claims methods that achieve an optimal pharmacokinetic profile for rapid relief of migraine with an emphasis on pulmonary administration of DHE, further strengthens our proprietary position for LEVADEX through 2028."
About MAP Pharmaceuticals
MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The New Drug Application for LEVADEX is currently under review by the U.S. Food and Drug Administration. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
LEVADEX has not been approved for marketing in the United States or any other country for any indication.
In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including, without limitation, risks and uncertainties relating to the regulatory approval process for the Company's LEVADEX product candidate and relating to the Company's patent rights. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, available at http://edgar.sec.gov.
Back to Archived News